Disarming Germs

From Gizmodo:

Developed by researchers at UCLA and the Geffen School of Medicine, the LpxC-1 antibiotic was developed to fight the drug-resistant Acinetobacter baumannii (pictured above), which commonly attacks hospital patients with open wounds or incisions. By turning off the toxins responsible for inflammation, the drug effectively neutralizes the cells without having to kill them off completely.